MedTrace Logo

A Clinical Trial for Post Traumatic Stress Disorder

NCT00554177 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-03-17

No results posted yet for this study

Summary

he purpose of this study is to test whether a medication, called mifepristone (commonly known as the ³Morning-After-Pill²), can help to prevent emotional problems after someone has survived a traumatic experience. We are studying this medication for the treatment of Post-traumatic Stress disorder (PTSD.

Conditions

  • Post Traumatic Stress Disorder (PTSD)

Interventions

DRUG

Medicane (mifepristone)

2 doses of 1200mg, Administered 2-3 days apart

DRUG

Placebo

2 doses of 1200mg, administered 2-3 days apart

Sponsors & Collaborators

  • Antonia New

    lead OTHER

Principal Investigators

  • Antonia New, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-09-30
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00554177 on ClinicalTrials.gov